1. Immunologic Diseases -- Graft Vs Host Disease Conversely, the transplanted immune cells can attack the tissues of the recipient, a potentially lifethreatening reaction called graft-vs-host disease. http://www.niaid.nih.gov/final/immds/grafhost.htm

50 YEARS NIAID HOMEPAGE INFECTIOUS DISEASES IMMUNOLOGIC DISEASES AIDS ... NIH HOMEPAGE The Immune System's Response to Transplants W hen tissue or organs from one person are transplanted into another, the recipient's immune system tries to get rid of this nonself tissue, a process called rejection. Conversely, the transplanted immune cells can attack the tissues of the recipient, a potentially life-threatening reaction called graft-vs-host disease. In 1980 three NIAID-supported scientists won the Nobel Prize in Physiology or Medicine for a discovery that revolutionized organ transplants. Tissue typing The researchers discovered a genetically determined group of cell and tissue "markers" called HLA antigens. Basic scientific research increases our understanding of the immune system's response to transplants. These, they found, were different in each person producing a biochemical profile as unique as a fingerprint.

2. September 1992 - Transfusion Associated Graft Vs. Host Disease And Irradiated Bl irradiation. Additional information about Transfusion Associated graft vs host disease can be obtained by contacting Darrell J. Triulzi, MD. http://www.itxm.org/Archive/tmu9-92.htm

September TRANSFUSION ASSOCIATED GRAFT VS. HOST DISEASE AND IRRADIATED BLOOD COMPONENTS Darrell J. Triulzi, M.D., Assistant Medical Director, Patient Transfusion Services INTRODUCTION Graft vs. host disease is a rare complication of transfusion. The disease results from transfusion of immunocompetent T cells capable of engrafting and initiating an immune response against recipient antigens. The most susceptible patient groups are those who are severely immunocompromised or are the recipients of directed donations from first-degree relatives. Transfusion associated graft vs. host disease (TAGVHD) can be prevented by gamma irradiation of cellular blood components (red cells, platelets, granulocytes). CLINICAL PRESENTATION TAGVHD has the same features as graft vs. host disease occurring in other settings such as allogeneic bone marrow transplantation. It typically occurs 3-30 days after transfusion of non-irradiated cellular products. The initial manifestations are often a high fever and an erythematous skin rash. Bone marrow aplasia and pancytopenia are also characteristic findings in TAGVHD. Other organs which may be involved include the gastrointestinal tract and liver. The diagnosis is made on the basis of a constellation of clinical features and can be confirmed by biopsy of the skin or other involved organs. This form of GVH has an extremely poor prognosis; the mortality rate approaches 90%. Unfortunately, there are no current effective therapies.

3. ClinicalTrials.gov - Information On Clinical Trials And Human Research Studies: Alphabetically G graft vs host disease. Include trials that are no longer recruiting patients. to Treat Chronic GraftVersus-Host Disease. Condition graft vs host disease http://clinicaltrials.gov/ct/gui/c/a1b/screen/BrowseAny?recruiting=true&path

4. Graft Vs Host Disease Treatments Bone Marrow Stem Cell Transplants graft vs host disease. Last update 04/28/2004. Topic Search http://www.lymphomation.org/bmt-gvhd.htm

ask question or sign Guest Book About Lymphoma Advocacy Art Clinical trials ... WebCasts Graft vs Host Disease Main Allogeneic Autologous Cord Blood ... Treatments Last update: Topic Search: PubMed: Donor CD4+CD25 Regulatory T-cells Approaches Novel Resources ... Research News Graft vs. Host Disease (GVHD) a frequent complication of allogeneic bone marrow transplant in which the donor's bone marrow cells attacks the patient's organs and tissue. GVHD tends to be more severe in patients receiving mismatched transplants from family member and in patients receiving unrelated donor transplants. Resources Descriptions - Johns Hopkins MSKCC som.ucsf.edu What can be done about chronic GVHD - Blood and Marrow Transplantation Reviews 2002 PDF PDF-Help "This is a review article looking at a variety of recent published research articles on the subject. It's a PDF file and it's long, so I have the link only for you, but it looks at things such as pentostatin in GvHD, extracoproreal photopheresis (ECP), and risk factors." - Scott S. Morbidity and Mortality of GVHD After Stem Cell Transplant Morbidity and Mortality of Chronic GVHD After Hematopoietic Stem Cell Transplantation From HLA-Identical Siblings for Patients With Aplastic or Refractory Anemias - Bloodline What is Graft-versus-Host-Disease ? -

5. LookSmart - Directory - Graft Vs Host Disease Or GVHD Host Dis. graft vs host disease or GVHD Covers causes, prevention, complications, and treatment. Includes information bone marrow transplant. http://search.looksmart.com/p/browse/us1/us317837/us317920/us53948/us217275/us93

@import url(/css/us/style.css); @import url(/css/us/searchResult1.css); Home IN the directory this category YOU ARE HERE Home Personal Health Immune Disorders ... Autoimmune Disease Graft vs Host Disease or GVHD - Covers causes, prevention, complications, and treatment. Includes information bone marrow transplant. Directory Listings About allRefer Health - Graft-Versus-Host Disease (GVHD) Information Profiles the prevention, risks, causes, symptoms, and treatment of this bone marrow transplant complication. People with bone marrow grafts are closely monitored. Graft v. Host Case Study Brief clinical but readable case study of a patient suffering from Graft v. Host disease. Graft-vs.-Host Disease - Gale Encyclopedia of Medicine Learn more about this condition in which the cells from a donor attack the host. NIAID - Graft v. Host disease Discover how the body deals with Graft v. Host, and how breakthroughs in organ transplants have cut down the risk of contracting this disease. We're always looking for ways to improve your search experience. Tell us how we're doing.

6. Graft Vs Host Disease Parker Hughes Cancer Center/ New Drug Effective Against Graft Versus Host Disease Offers Hope to Bone Marrow Transplant Recipients 831-01 ROSEVILLE, Minn. http://organtx.org/dc/gvh2001.htm

Graft vs Host Disease Immunoglobulin Mechanism in GVHD Elucidated LONDON (Reuters Health) 10-23-01 Intravenous immunoglobulin (IVIg) decreases the severity of acute graft-versus-host disease (GVHD) by inducing apoptosis of donor T cells, French researchers conclude after completing a series of animal experiments. Dr. Blanche Bellon, and colleagues at INSERM in Paris, induced acute GVHD in rats, which were then given IVIg, F(ab')2 fragments, or no treatment. Seventy-two percent of the rats that did not receive IVIg or F(ab')2 fragments were dead within 20 days, they report in the September issue of the European Journal of Immunology. In contrast, only 39% of the IVIg-treated and 20% of the F(ab')-treated rats had died or had clinical symptoms of GVHD. In further experiments, acute GVHD was induced by transferring cells from male rats to female rats. The investigators found that IVIg induced apoptosis of the allogeneic donor CD4+CD134+ Th1 cytokine-producing T cells and dramatically reduced 0X40 antigen on CD4+ cells, thereby preventing GVHD in the treated rats, according to the report. "Our present observations provide a specific mechanism for immunomodulation of GVHD by IVIg and emphasize the role of normal immunoglobulins in alloantigen immune responsiveness that develops in both deleterious graft-versus-donor and beneficial graft-versus- leukemia reactions," Dr. Bellon and colleagues conclude.

7. Inflammatory Myopathy Graftvs-host disease, 7 to 24 months post BMT. graft vs host disease (GVHD) + Myositis 30 Relation to transplant (bone marrow or stem cell) http://www.neuro.wustl.edu/neuromuscular/antibody/infmyop.htm

Front Search Index Links ... Patient Info Inflammatory and Immune Myopathies GENERAL FEATURES Antibodies CK: Serum Electrodiagnostic ... Calcinosis : X-rays Chondroitin sulfate C deficient Dermatomyositis Fasciitis Focal myositis ... Signal recognition particle Vasculitis: Small Large vessel SPECIFIC IMMUNE OR INFLAMMATORY MYOPATHIES Immune myopathies (Polymyositis) General aspects Classification Comparative features Collagen vascular disease Complement ... Quadriceps ; Other TRAPS Granulomatous Hemophagocytic lymphohistiocytosis Hereditary ... Multinodular polymyositis Necrotizing with Encephalopathy Paraneoplastic with Pipestem capillaries SRP antibodies ... MHC class I upregulation Skin lesions Erythema Gottron's papules Nailfold lesions From: Chinju, South Korea GENERAL FEATURES OF INFLAMMATORY MYOPATHIES Antibodies CK: Serum Electrodiagnostic Neoplasm associations ... Weakness Skin lesions Heliotrope rash Distribution Symmetric Disease association: Dermatomyositis External links Facial rash Gottron's sign Red-purple keratotic, atrophic erythema, or macules Disease association: Dermatomyositis External link: Gottron's sign Erythema Red-purple slightly raised On extensor surfaces of elbows or knees Disease association: Dermatomyositis Mechanic's hands Raised scaly dry On extensor surfaces of finger joints Disease association: Nailfold lesions Disease association: Dermatomyositis - Anti-Mi-2 antibody positive Other features Rash more commonly pruritic than rash with lupus erythematosis Skin lesions often photoaggravated Weakness Proximal: Most Dermatomyositis Polymyositis Distal:

8. Penn State Faculty Research Expertise Database (FRED) Faculty Research Expertise Database. graft vs host disease. Runt Disease, Graftvs-Host Disease. Disease, Graft-Versus-Host, Disease, Graft-vs-Host. http://fred.hmc.psu.edu/ds/retrieve/fred/meshdescriptor/D006086

9. ASCO - Browse By Meeting - Treatment Of Refractory Chronic Graft-vs-host Disease Abstract Chronic graft vs host disease (CGVHD) is the most common late complication of allogeneic BMT. This is a significant problem http://www.asco.org/ac/1,1003,_12-002636-00_18-0023-00_19-00103023,00.asp

HOME ABOUT ASCO PRESS CENTER STATE AFFILIATES ... Career Resources Pay Membership Dues, Membership Directory, Drug Database, Update Your Profile username password Remember Me Forgot your password? Create a guest account BECOME A MEMBER Journal of Clinical Oncology The ASCO Foundation People Living With Cancer BECOME A SPONSOR The remember me feature is an automatic login process which creates a cookie on the hard drive of your computer containing your username and password, thereby avoiding the need to enter them upon subsequent visits to asco.org. DO NOT select this option if you share this computer with others since personal or member only information will be accessible by other users. For addition information please review our . Click OK to keep the Remember Me option, or click Cancel to remove it. When you are done, click the LOGIN button to continue with the login Process . Home Abstracts Browse by Meeting Meeting: 2003 ASCO Annual Meeting Printer Friendly Bookmark Category: Transplantation SubCategory: Allogeneic Bone Marrow Transplantation Treatment of refractory chronic graft-vs-host disease with infliximab Abstract No: Citation: Proc Am Soc Clin Oncol 22: page 836, 2003 (abstr 3358)

10. Genomics|HuGENet EJournal On Graft Vs Host Disease The Health Outcome. Graft versus Host Disease (GVHD) is a condition that can result from hematopoietic cell transplant (HCT). It http://www.cdc.gov/genomics/hugenet/ejournal/GraftVsHost.htm

Your browser does not support script home ejournal Relation of an Interleukin-10 Promoter Polymorphism to Graft-versus-Host Disease and Survival after Hematopoietic-Cell Transplantation ejournal abstract template on Lin M, et al. May 6, 2004 Access past issues Reviewed by: Jennifer Kuzara Emory University Department of Anthropology; Rollins School of Public Health Department of Epidemiology The Health Outcome Graft versus Host Disease (GVHD) is a condition that can result from hematopoietic cell transplant (HCT). It affects a large percentage of individuals who receive HCT; the chronic form occurs in 50% of HLA-matched sibling transplants, and in 64% of patients whose donors were HLA-unmatched. Frequency of the acute form varies widely according to other risk factors such as age and underlying illness: from 19% to 66% in HLA-matched transplant patients, and 70% to 90% of HLA-unmatched transplants patients ( The effects of donor-T-cell alloresponse can take both acute and chronic forms. The acute form occurs within 30 days of transplant. The symptoms are characteristic of systemic cytokine overload. The chronic form usually follows the acute form, though it can also occur de novo. It resembles an autoimmune syndrome and is generally expressed in epidermal tissues. Lin et al. propose that single-nucleotide polymorphisms in various cytokines may affect the outcome of GVHD by reducing or enhancing the inflammatory response of the recipient. Only

11. Entrez PubMed Female; Genes*; graft vs host disease/genetics*; graft vs host disease/immunology; graft vs host disease/pathology; Immunization, Passive; http://www.biomedcentral.com/pubmed/3891901

Entrez PubMed Nucleotide Protein ... Books Search PubMed Protein Nucleotide Structure Genome Books CancerChromosomes 3D Domains Domains Gene GEO GEO DataSets HomoloGene Journals MeSH NCBI Web Site OMIM PMC PopSet SNP Taxonomy UniGene UniSTS for Limits Preview/Index History Clipboard ... Text Version Entrez PubMed Overview FAQ Tutorial New/Noteworthy ... E-Utilities PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher ... Cubby Related Resources Order Documents NLM Gateway TOXNET Consumer Health ... PubMed Central Summary Brief Abstract Citation ASN.1 MEDLINE XML UI List LinkOut Related Articles Cited in Books CancerChrom Links Domain Links 3D Domain Links GEO DataSet Links Gene Links Genome Links GEO Links HomoloGene Links Nucleotide Links OMIM Links PMC Links Cited in PMC PopSet Links Protein Links SNP Links Structure Links UniSTS Links Show: Sort Author Journal Pub Date Text File Clipboard E-mail Order J Exp Med. 1985 Jul 1;162(1):1-18. Related Articles, Links Association of lpr gene with graft-vs.-host disease-like syndrome. Theofilopoulos AN, Balderas RS, Gozes Y, Aguado MT, Hang LM, Morrow PR, Dixon FJ. Publication Types: Review PMID: 3891901 [PubMed - indexed for MEDLINE] Summary Brief Abstract Citation ASN.1

12. Entrez PubMed DiseaseFree Survival; Female; graft vs host disease/diagnosis; graft vs host disease/pathology*; Human; Infant; Intestinal Diseases/diagnosis; http://www.biomedcentral.com/pubmed/12931120

Entrez PubMed Nucleotide Protein ... Books Search PubMed Protein Nucleotide Structure Genome Books CancerChromosomes 3D Domains Domains Gene GEO GEO DataSets HomoloGene Journals MeSH NCBI Web Site OMIM PMC PopSet SNP Taxonomy UniGene UniSTS for Limits Preview/Index History Clipboard ... Text Version Entrez PubMed Overview FAQ Tutorial New/Noteworthy ... E-Utilities PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher ... Cubby Related Resources Order Documents NLM Gateway TOXNET Consumer Health ... PubMed Central Summary Brief Abstract Citation ASN.1 MEDLINE XML UI List LinkOut Related Articles Cited in Books CancerChrom Links Domain Links 3D Domain Links GEO DataSet Links Gene Links Genome Links GEO Links HomoloGene Links Nucleotide Links OMIM Links PMC Links Cited in PMC PopSet Links Protein Links SNP Links Structure Links UniSTS Links Show: Sort Author Journal Pub Date Text File Clipboard E-mail Order Biol Blood Marrow Transplant. 2003 Aug;9(8):512-8. Related Articles, Links Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Weisdorf DJ, Hurd D, Carter S, Howe C, Jensen LA, Wagner J, Stablein D, Thompson J, Kernan NA.

13. PharmGKB: Graft Vs Host Disease graft vs host disease. Alternate Names Disease, GraftVersus-Host; Disease, Graft-vs-Host; Disease, Homologous Wasting; Disease, Runt http://www.pharmgkb.org/do/serve?objId=PA444320&objCls=Disease

14. Graft Vs Host Disease graft vs host disease Companies with products addressing GVHD. Company Rankings, Symbol, Product, Development Stage. Abgenix, ABGX, ABXCBL, Phase III. http://www.bitsplace.com/bitsplace/GVHDcomp.html

Graft vs Host Disease Companies with products addressing GVHD. Company Rankings Symbol Product Development Stage Abgenix ABGX ABX-CBL Phase III Protein Design Labs PDLI Zenapax Phase II Medimmune MEDI MEDI-507 Phase I/II ABX-CBL a monoclonal antibody produced with ABGX's Xenomouse GVHD most acute in bone marrow transplants current therapy includes steroids and horse antibody ATG - anti-thymocyte globulin from horses ABX-CBL intended to avoid steroid resistance CBL antigen on T cells, B cells and natural killer cells ABX-CBL targets only these cells immune suppression less than conventional therapy long term survival should be greater Medi-507 anti-CD2 humanized monoclonal antibody (MAB) binds to CD2 receptor of T cells and NK cells inhibits immune response to transplanted tissue does not inhibit normal immune function intended for use in GvHD (graft vs host disease) GvHD develops in bone marrow and stem cell transplants transplanted cells attack recipient's tissues 70% mortality rates 30,000 bone marrow or stem cell transplants/year MEDI-507 has been granted orphan drug status by FDA benefits for developing drug with small patient pool Zenapax (daclizumab; SMART Anti-Tac Antibody)

15. Blackwell Synergy - Cookie Absent Lichenoid graft vs. host disease following liver transplantation. graft vs host disease after liver transplantation in humans a report of four cases. http://www.blackwell-synergy.com/links/doi/10.1111/j.0303-6987.2004.00146.x/abs/

 Home An Error Occurred Setting Your User Cookie A cookie is a small amount of information that a web site copies onto your hard drive. Synergy uses cookies to improve performance by remembering that you are logged in when you go from page to page. If the cookie cannot be set correctly, then Synergy cannot determine whether you are logged in and a new session will be created for each page you visit. This slows the system down. Therefore, you must accept the Synergy cookie to use the system. What Gets Stored in a Cookie? Synergy only stores a session ID in the cookie, no other information is captured. In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a web site to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it. Please read our for more information about data collected on this site.

16. Gr : On Medical Dictionary Online Graft Restenoses, Vascular Graft Restenosis, Vascular Graft Survival Graft Survivals Graft Tolerance Graft Versus Host Disease graft vs host disease Graft vs http://www.online-medical-dictionary.org/?q=~Gr

17. ClinicalTrials.gov - Information On Clinical Trials And Human Research Studies: 38 studies were found. 1. Recruiting, Extracorporeal Photopheresis to Treat Chronic GraftVersus-Host Disease Condition graft vs host disease. http://www.clinicaltrials.gov/ct/search?term=GVHD [CONDITION]&submit=Search

18. Graft Vs Host Disease Wound Management Forum Archive (1999-2000). Next-in-Thread Next Message Question graft vs host disease. Add Message to graft vs host disease . http://www.smtl.co.uk/cgi-bin/HyperNews/get.cgi/wounds-archive/67.html?nogifs

19. Surgeons Net Web Directory - Home > Transplant Surgery > Graft Vs Host Disease ADVERTISEMENT. Register with SurgeonsNet Free Email. Home/ Transplant Surgery/ graft vs host disease/. Control of Graft Versus Host http://www.surgeons.org.uk/search/Transplant_Surgery/Graft_vs_Host_Disease/

Free Email Home Transplant Surgery/ Graft vs Host Disease/ Control of Graft Versus Host Disease - from Frontiers in Bioscience. Graft Versus Host Disease Graft Versus Host Disease (GVHD) - info from the Johns Hopkins Oncology Centre's Hematologic Malignancies Division. Rare Diseases Clinical Trials - clinical trials pertaining to Graft Versus Host Disease. We subscribe to the HONcode principles of the Health On the Net Foundation Surgeons Net Ltd Terms and Conditions Advertising Policy ... Discussion Last modified: August 29 2002 01:07:14.

20. Entrez PubMed Click here to read Chronic graftvs-host disease. Publication Types Review; Review, Tutorial. MeSH Terms Chronic Disease; graft vs host disease*/diagnosis; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 1     1-20 of 90    1  | 2  | 3  | 4  | 5  | Next 20